A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases,
which can be promoted by interleukin-2 (IL-2). In a previous small sample trail performed by
the investigator's group, the investigators found that the Low-dose IL-2 was effective and
well tolerated in active SLE, and the effect was associated with selective modulation of CD4+
T cell subsets.
This clinical study will confirm the efficacy and safety of low dose IL-2 treatment in SLE.
The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in SLE.The
investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for Systemic lupus
erythematosus by randomized controlled study (hrIL-2 (N = 30) versus placebo group (N = 30)).
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing ShuangLu Pharmaceutical Co., Ltd. Monash University